Several studies have shown that DDB2 inhibits the NF-kB pathway and the activity of stem cell markers, acetaldehyde dehydrogenase (ALDH+) or CD44+CD117+, to reduce the abundance of ovarian CSCs, elucidating a new mechanism for the DDB2-induced inhibition of cancer cell tumorigenicity [82]. This evidence concerns the gene NFKB1 and cancer.